<DOC>
	<DOCNO>NCT00394693</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy four-month dosing period intra-lesional injection TG1042 patient relapse CBCL . Patients receive intra-tumoral injection adenoviral vector construct contain human interferon gamma gene ( TG1042 ) , attempt enhance immune response anti-tumor activity . This local administration induces tumour cell kill injected tumour site .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Adeno-IFN Gamma Cutaneous B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Patients must satisfy follow criterion entry protocol : Primary CBCL include ( accord WHO/EORTC classification 2005 ) : Primary cutaneous marginal zone Bcell lymphoma Primary cutaneous follicle center Bcell lymphoma Primary cutaneous diffuse large Bcell leg type Histologically consistent primary CBCL . Relapse active disease radiotherapy adequate therapy radiotherapy contraindicate ( chemotherapy , surgical excision , interferonα , rituximab ) . Performance status 0 , 1 Eastern Cooperative Oncology Group ( ECOG ) scale ( See Appendix E ) . Minimum Life Expectancy &gt; 3 month . Adequate blood count : hemoglobin &gt; = 10.0 g/dL ; White Blood Count ( WBC ) &gt; = 3.0 x 109/L ; platelet count &gt; = 75 x 109/L . Adequate hepatic function : bilirubin = &lt; 1.5 time upper limit normal serum transaminase ( SGOT SGPT ) = &lt; 2.5 time upper limit normal . Adequate renal function : creatinine = &lt; 1.5 time upper limit normal . Written informed consent patient . Patients exclude study follow reason : Primary cutaneous diffuse large Bcell lymphoma , leg type . Primary cutaneous intravascular large Bcell lymphoma . Extracutaneous involvement ( sign Bcell lymphoma thoracoabdominal CT scan and/or PET scan and/or bone marrow biopsy ) . No histologic documentation CBCL . History known Human Immunodeficiency Virus , Human Hepatitis B C positive serology active systemic infection . Serious uncontrolled , concomitant medical disorder . Concomitant therapy CBCL : surgical resection , radiotherapy , corticosteroid , chemotherapy , rituximab… ( limited listing ) Major surgery previous 4 week precede 1st injection . Pregnancy study entry become pregnant study woman breast feeding . Males female reproductive potential refuse use adequate protection pregnancy ( intrauterine device , hormonal contraception diaphragm/condom spermicide ) conduct study three month last injection . Participation another experimental protocol study period within 4 week prior first injection . Patient previously include study . Non compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Primary CBCL include ( WHO/EORTC classification 2005 )</keyword>
	<keyword>Primary cutaneous marginal zone B-cell lymphoma</keyword>
	<keyword>Primary cutaneous follicle center B-cell lymphoma</keyword>
	<keyword>Primary cutaneous diffuse large B-cell leg type</keyword>
	<keyword>Histologically consistent primary CBCL</keyword>
	<keyword>Relapse active disease</keyword>
</DOC>